MTOR and colorectal carcinoma: The remarkable role of immunosuppression profiles was consistently highlighted: cyclosporine—azathioprine maintenance and alemtuzumab induction were associated with higher CRC risk in large registries, whereas tacrolimus—mycophenolate regimens showed lower risk signals and mTOR inhibitors suggested possible protective effects.